Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals
Epic: APH
News: Latest news
Web Site: Alliance Pharma
Other Articles: 05-07-201022-06-201027-05-2010

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday September 09, 12:27ZOO Digital’s new iTunes toolset adopted by major Hollywood studio

The new iTunes toolkit automates the production of menus and bonus features, allowing studios to produce enhanced download content at significantly lower costs. The toolkit is expected to open-up 'a large potential market' and add new revenue streams.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday September 08, 10:42African Energy Resources encouraged by coal results at Sese, seeks cornerstone partner

With the coal quality, thickness and shallow depth, it augurs well for potential commercial coal production for African Energy at Sese in Botswana.

FULL ARTICLE ►

RSS - Subscribe to the News Today on Proactive CN ▼

Tuesday September 07, 08:12MetroCoal re-affirms Columboola coal Resource yet to be completed

Emerging coal-focused energy company MetroCoal (ASX: MTE) has clarified that it has not completed any resource estimate or report on its Columboola Project area in Queensland's Surat Basin.

FULL ARTICLE ►
Alliance Pharma

Alliance Pharma

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

CLICK HERE FOR FULL ANLAYSIS OF ALLIANCE PHARMA
Monday, March 15, 2010

Alliance Pharma shareholder Nigel Wray buys 200,000 more shares

Alliance Pharma (AIM: APH) announced that Nigel Wray has bought a further 200,000 shares in the company to take his holding to 24,519,995 shares, or 11.04% of the capital. He is still the group's second largest shareholder behind chief executive John Dawson.

Alliance Pharma (AIM: APH) last month completed the acquisition of Cambridge Laboratories. The deal, which adds 18 new prescription products to Alliance’s portfolio, is expedted to be significantly earnings enhancing in the current financial year. Cambridge’s commercial manager Peter Butterfield has also been appointed to the Alliance Pharma board.

The deal is worth between £14.3m and £16.4m, plus an additional £1.4m for Cambridge’s product inventory.

Back in January, Alliance said it expected to report turnover for the full year to 31 December 2009 of approximately £31 million, an increase of approximately 42% on the previous year.

Shares in Alliance have performed very well over the past six months as the stock’s value almost doubled from below 20 pence to the current 35 pence.

AddThis Feed Button
Register here to be notified of future Alliance Pharma articles.

Other Alliance Pharma news

More news ►

Investors interested in Alliance Pharma recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.